Antenatal diagnosis and maternal sirolimus treatment of polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome
Pregnancy · 2026-05 · 2 (3)
DOI: 10.1002/pmf2.70297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pregnancy, online erschienen am 29.04.2026. Verfasst von Christian Macedonia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences University of Michigan College of Pharmacy Ann Arbor Michigan USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome is a rare autosomal recessive mTORopathy caused by biallelic STE20‐related kinase adaptor alpha ( STRADA ) loss‐of‐function variants. Animal models demonstrate that in utero mechanistic target of rapamycin (mTOR) inhibition can prevent cortical dyslamination, suggesting a prenatal therapeutic window.
Methods
A gravida 3 para 2 patient presented at 32+2 weeks with medication‐refractory preterm labor and severe polyhydramnios. Fetal magnetic resonance imaging (MRI) demonstrated macrocephaly and an enlarged cavum septum pellucidum (CSP). Amniocentesis with microarray revealed homozygosity across the STRADA locus; sequencing confirmed the founder STRADA exons 9–13 deletion. After counseling, maternal sirolimus therapy was initiated at 35+6 weeks using a 20 mg loading regimen followed by 6–8 mg/day maintenance dosing. Serial ultrasound monitored fetal biometry and CSP size. Delivery occurred at 39+1 weeks. Pediatric follow‐up was extended nearly 5 years.
Results
Maternal sirolimus was well tolerated. Amniotic fluid index (AFI) declined from 36.1 to 26.2 cm, head circumference normalized from the 89th to 35th percentile, and CSP diameter decreased from 14.0 to 12.3 mm. A term vaginal delivery produced a 3554 g infant with normocephaly. Cord blood sirolimus level (3.9 mcg/L) approximated maternal level (3.4 mcg/L). Postnatally, sirolimus was continued from day of life 7. The first seizure occurred at 4.5 months, coincident with subtherapeutic trough levels; seizure control was achieved thereafter. At nearly 5 years, the child shows adequate growth but severe global developmental delay typical of PMSE. This case demonstrates the feasibility and pharmacokinetic effectiveness of maternal sirolimus during late gestation, with no identified maternal or fetal adverse consequences in this first case of third‐trimester prenatal mTOR inhibition in confirmed PMSE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences University of Michigan College of Pharmacy Ann Arbor Michigan USA.
- Clinic For Special Children Lancaster Pennsylvania USA.
- The Central Pennsylvania Clinic Bellville Pennsylvania USA.
- Department of Gynecology and Obstetrics Johns Hopkins University School of Medicine Baltimore Maryland USA.
- Icahn School of Medicine at Mount Sinai New York New York USA.
- Department of Neurology University of Maryland Baltimore Maryland USA.
ORCID-Profile: Christian Macedonia
Zitieren
APA
Macedonia, C., Carson, V. J., Morton, D. H., Blakemore, K. J., Evans, M. I., & Crino, P. B. (2026). Antenatal diagnosis and maternal sirolimus treatment of polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Pregnancy, 2(3). https://doi.org/10.1002/pmf2.70297
Vancouver
Macedonia C, Carson VJ, Morton DH, Blakemore KJ, Evans MI, Crino PB. Antenatal diagnosis and maternal sirolimus treatment of polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Pregnancy. 2026;2(3). doi:10.1002/pmf2.70297
BibTeX
@article{Macedonia2026,
author = {Macedonia, Christian and Carson, Vincent J and Morton, D Holmes and Blakemore, Karin J and Evans, Mark I and Crino, Peter B},
title = {Antenatal diagnosis and maternal sirolimus treatment of polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome},
journal = {Pregnancy},
year = {2026},
volume = {2},
number = {3},
doi = {10.1002/pmf2.70297}
}
EUVIMED